801 related articles for article (PubMed ID: 15294013)
1. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
3. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
6. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
7. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
Nelson HS; Busse WW; Kerwin E; Church N; Emmett A; Rickard K; Knobil K
J Allergy Clin Immunol; 2000 Dec; 106(6):1088-95. PubMed ID: 11112891
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
[TBL] [Abstract][Full Text] [Related]
9. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.
Lenney W; McKay AJ; Tudur Smith C; Williamson PR; James M; Price D;
Health Technol Assess; 2013 Feb; 17(4):1-218. PubMed ID: 23380178
[TBL] [Abstract][Full Text] [Related]
10. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
11. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
Balkrishnan R; Nelsen LM; Kulkarni AS; Pleasants RA; Whitmire JT; Schechter MS
J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
13. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
14. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Stoloff SW; Stempel DA; Meyer J; Stanford RH; Carranza Rosenzweig JR
J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
17. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
Bateman ED; Silins V; Bogolubov M
Respir Med; 2001 Feb; 95(2):136-46. PubMed ID: 11217910
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of strategies for reducing treatment in mild persistent asthma.
; Peters SP; Anthonisen N; Castro M; Holbrook JT; Irvin CG; Smith LJ; Wise RA
N Engl J Med; 2007 May; 356(20):2027-39. PubMed ID: 17507702
[TBL] [Abstract][Full Text] [Related]
19. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma.
Ringdal N; Eliraz A; Pruzinec R; Weber HH; Mulder PG; Akveld M; Bateman ED;
Respir Med; 2003 Mar; 97(3):234-41. PubMed ID: 12645830
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]